Cargando…
Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia
INTRODUCTION: Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder and regarded as one of the most frequent genetic causes of infant mortality. The aim of this study is to develop a cost-effectiveness analysis of AVXS-101 (Onasemnogene Abeparvovec/Zolgensma(®)) and nusinersen (Spinra...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618547/ https://www.ncbi.nlm.nih.gov/pubmed/35980467 http://dx.doi.org/10.1007/s00415-022-11319-0 |